Related Experiment Video
Updated: May 12, 2026
05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Predictive Modelling Risk Calculators and the Non Dialysis Pathway.
1Depts Renal Medicine and Medicine, St George Hospital and University of NSW, Sydney, NSW.
Nephrology (Carlton, Vic.)
|April 17, 2013
Summary
Predictive models aid decisions for advanced kidney disease patients choosing non-dialysis care. These tools help personalize treatment by assessing survival and quality of life, improving patient outcomes.
Area of Science:
- Nephrology
- Geriatrics
- Palliative Care
Background:
- Risk prediction is crucial for advanced kidney disease (CKD) management.
- Emerging evidence suggests individualized risk prediction improves patient outcomes.
- Non-dialysis treatment pathways require careful consideration for elderly patients with comorbidities.
Purpose of the Study:
- To review current prediction models and survival/mortality scores for advanced kidney disease.
- To inform clinical decision-making for patients considering non-dialysis treatment.
- To guide discussions between nephrologists, palliative care specialists, patients, and families regarding dialysis suitability.
Main Methods:
- Review of current prediction models and survival/mortality scores.
- Analysis of observational trials guiding clinical decision-making in end-stage kidney disease (ESKD).
- Evaluation of factors influencing treatment pathway selection, including quality of life and functional status.
Main Results:
- Predictive models are essential tools for nephrologists and renal palliative care specialists.
- Individualized risk prediction can lead to improved patient outcomes in advanced CKD.
- Survival benefits of renal replacement therapy may be offset by reduced quality of life and increased complications in elderly, comorbid patients.
Conclusions:
- Current guidelines for non-dialysis pathways in advanced kidney disease rely on observational data.
- Predictive models are vital for informed decision-making in end-stage kidney disease (ESKD) patient care.
- Non-dialysis pathways offer an alternative that may preserve quality of life for select elderly patients with multiple comorbidities.
Related Concept Videos
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:07Determination of Renal Drug Clearance: Graphical and Midpoint Methods
Renal clearance, a crucial parameter in pharmacokinetics, can be determined using two different methods: the graphical method and the midpoint method. These methods provide insights into the rate of drug excretion by the kidneys and aid in assessing renal function.
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...
01:25Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
01:11Hazard Rate
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...